NASDAQ$INGN
Inogen Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Inogen's revenue decreased slightly, but rental revenue grew significantly, and the company reported a net loss.
Inogen reported a slight decrease in total revenue for Q1 2021, with a net loss of $0.7 million. However, the company saw strong growth in rental revenue and sequential growth in all four sales channels.
- Total revenue decreased by 1.8% compared to the same period in 2020, totaling $86.9 million.
- Rental revenue increased significantly by 84.2% compared to Q1 2020, reaching $9.9 million.
- Domestic business-to-business revenue increased by 11.6% compared to the same period in 2020, reaching $30.7 million.
- The company's cash, cash equivalents, and marketable securities totaled $233.2 million as of March 31, 2021, with no outstanding debt.
Headline financials
Revenue & EPS history
Inogen · Revenue · Quarterly
$86.9M
Forward guidance
Due to COVID-19 uncertainties, Inogen is unable to provide full-year 2021 guidance. However, they anticipate increased operating expenses due to investments in clinical research, R&D, and infrastructure to support their rental-focused strategy. They expect all sales channels to increase in Q2 2021 compared to the previous year, with the rental channel showing the largest percentage growth.
Tailwinds
- Company expects all sales channels to increase versus the comparative period in the prior year.
- Largest percentage growth expected in its rental channel.
- Company expects to continue to see the largest COVID-19 related impact on its international business-to-business sales channel.
- Company believes it is prudent to continue to make investments in clinical research.
- Company believes it is prudent to continue to make investments in research and development
Headwinds
- Because of the uncertainties related to the COVID-19 pandemic, the Company is still unable to provide guidance for the full year 2021.
- Given the uncertain scope and duration of the COVID-19 pandemic, the Company is unable to estimate the related impact on its financial results, including revenue, net income or loss, and Adjusted EBITDA estimates for such period.
- Company expects increased operating expense for the year in 2021.
- Company incurred minimal expenses related to bonus and performance-based stock-based compensation in 2020, it expects such costs to increase in 2021 along with certain expenses related to the previously announced recent officer transitions.
- Company expects to continue to see the largest COVID-19 related impact on its international business-to-business sales channel primarily due to the continued reduced operational capacity of the respiratory assessment centers and slower vaccine rollouts than the United States.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.7%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-2.0%
Avg return
30 days after
49%
26 / 53 earnings
Positive
+35.5%
Q2 2024
Best reaction
-32.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -5.3% | -11.0% | |
| Q4 2025 | +4.3% | +5.8% | +6.0% | |
| Q3 2025 | -0.6% | +0.9% | -1.3% | |
| Q1 2025 | -11.5% | -14.4% | -8.1% | |
| Q4 2024 | -14.8% | -14.6% | -28.6% | |
| Q3 2024 | +15.9% | +9.1% | -0.7% | |
| Q2 2024 | +35.5% | +50.6% | +43.0% | |
| Q1 2024 | +14.6% | +17.7% | +17.7% | |
| Q4 2023 | -32.2% | -24.3% | -13.0% | |
| Q3 2023 | -1.3% | -8.1% | +10.0% | |
| Q2 2023 | -14.6% | -18.7% | -20.8% | |
| Q1 2023 | -6.1% | -19.3% | -21.9% | |
| Q4 2022 | -31.4% | -32.4% | -46.4% | |
| Q3 2022 | -12.5% | -10.0% | -0.8% | |
| Q2 2022 | -6.9% | -7.3% | -6.3% | |
| Q1 2022 | -2.2% | -7.8% | +2.0% | |
| Q4 2021 | +12.6% | +25.3% | +13.5% | |
| Q3 2021 | -6.0% | -7.3% | -21.6% | |
| Q2 2021 | -22.8% | -16.8% | -22.1% | |
| Q1 2021 | -3.5% | -2.4% | -12.8% | |
| Q4 2020 | +4.6% | +5.4% | -4.2% | |
| Q3 2020 | -7.1% | +9.8% | +33.0% | |
| Q2 2020 | +16.4% | +17.0% | -6.5% | |
| Q1 2020 | -21.4% | -20.1% | -24.2% | |
| Q4 2019 | +10.2% | +5.4% | +26.4% | |
| Q3 2019 | +17.3% | +19.7% | +24.4% | |
| Q2 2019 | -15.4% | -18.5% | -20.9% | |
| Q1 2019 | -28.8% | -22.2% | -31.8% | |
| Q4 2018 | -26.4% | -25.9% | -35.1% | |
| Q3 2018 | -18.8% | -22.6% | -24.8% | |
| Q2 2018 | +7.7% | +6.3% | +21.3% | |
| Q1 2018 | +21.0% | +18.7% | +26.7% | |
| Q4 2017 | -9.3% | -8.4% | -7.8% | |
| Q3 2017 | +16.1% | +12.9% | +15.0% | |
| Q2 2017 | -5.6% | -3.9% | +0.3% | |
| Q1 2017 | +0.2% | -2.6% | +11.9% | |
| Q4 2016 | +6.8% | +6.0% | +11.4% | |
| Q3 2016 | +13.0% | +15.8% | +22.3% | |
| Q2 2016 | +0.9% | +9.3% | +8.9% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +20.6% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +4.9% | — | — | |
| Q4 2014 | +1.8% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2013 | -1.7% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +3.6% | — | — | |
| Q2 2013 | +3.6% | — | — | |
| Q1 2013 | +12.7% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro